



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/045,949	(01/11/2002	Kenneth A. Davis	BDIS-20	2520
1473	7590	05/12/2004		EXAMINER	
FISH & N	EAVE		VANDERVEGT, FRANCOIS P		
1251 AVENUE OF THE AMERICAS 50TH FLOOR				ART UNIT	PAPER NUMBER
NEW YOR	NEW YORK, NY 10020-1105			1644	
				DATE MAILED 05/13/200	

Please find below and/or attached an Office communication concerning this application or proceeding.

A :	Application No.	Applicant(s)	
	10/045,949	DAVIS, KENNETH et al.	
Office Action Summary	Examiner	Art Unit	
	F. Pierre VanderVegt	1644	
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with th	ne correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPITHE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory perior - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	. 136(a). In no event, however, may a reply be ply within the statutory minimum of thirty (30) at will apply and will expire SIX (6) MONTHS to be cause the application to become ABANDO	e timely filed days will be considered timely. from the mailing date of this communication. ONED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on	·		
==/	is action is non-final.		
3) Since this application is in condition for allow			
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11	, 453 O.G. 213.	
Disposition of Claims	•		
4) Claim(s) 1-24 is/are pending in the application	n.		
4a) Of the above claim(s) is/are withdr	awn from consideration.		
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.	- alastian requirement		
8) Claim(s) <u>1-24</u> are subject to restriction and/o	r election requirement.		
Application Papers			
9) ☐ The specification is objected to by the Exami		·	
10)☐ The drawing(s) filed on is/are: a)☐ ad			
Applicant may not request that any objection to the			
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the	ection is required if the drawing(s) is Examiner. Note the attached Of	s objected to. See 37 CFR 1.121(d). ffice Action or form PTO-152.	
Priority under 35 U.S.C. § 119			
12) ☐ Acknowledgment is made of a claim for foreignal ☐ All b) ☐ Some * c) ☐ None of:	gn priority under 35 U.S.C. § 11	9(a)-(d) or (f).	
 Certified copies of the priority docume 			
2. Certified copies of the priority docume			
3. Copies of the certified copies of the pr		beived in this National Stage	
application from the International Bure		eived	
* See the attached detailed Office action for a li	st of the certified copies not rec		
Attachment(s)	_		
1) Notice of References Cited (PTO-892)	4) Interview Sum Paper No(s)/M	mary (PTO-413) ail Date	
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date	E) Netice of Infor	mal Patent Application (PTO-152)	
S. Patent and Trademark Office			

Application/Control Number: 10/045,949

Art Unit: 1644

DETAILED ACTION

This application claims the benefit of the filing date of provisional application 60/261,448.

Claims 1-24 are originally pending.

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-24, drawn to a fluorescently labeled multimeric complex comprising MHC class I domain moieties, a method of labeling T cells and a kit comprising the complex, classified in class 530, subclass 350.
 - II. Claims 1-24, drawn to a fluorescently labeled multimeric complex comprising MHC class II domain moieties, a method of labeling T cells and a kit comprising the complex, classified in class 530, subclass 350.
 - III. Claim 10, drawn to a fluorescently labeled multimeric antibody complex specific for the antigen receptor of a CD8+ T cell, classified in class 530, subclass 388.22.
 - IV. Claim 10, drawn to a fluorescently labeled multimeric antibody complex specific for the antigen receptor of a CD4+ T cell, classified in class 530, subclass 388.22.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions I & II and III & IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to recombinant MHC multimers in Groups I & II that interact with antigenic peptides and with T cells in a different manner than the antibody complexes of Groups III & IV.
- 3. Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to recombinant MHC class I domain moieties in Group I that recognize different peptides, have a structurally different peptide-binding pocket and associate with a different subset of T cells than the MHC class II domain moieties of Group II.
- 4. Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to antibodies that are specific for the antigen receptor of a T cell and the antigen receptor of CD4+ T cells

Application/Control Number: 10/045,949

Art Unit: 1644

is different from the antigen receptor of CD8+ T cells, recognizing antigenic fragments in the context of a different type of MHC molecule.

- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 6. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to F. Pierre VanderVegt whose telephone number is (571) 272-0852. The examiner can normally be reached on M-Th 6:30-4:00; Alternate Fridays 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

F. Pierre VanderVegt, Ph.D.

Patent Examiner April 12, 2004 PATRICK J. NOLAN, PH.D.

PRIMARY EXAMINER